Morgan Stanley’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $83.3M | Buy |
2,055,718
+42,941
| +2% | +$1.74M | 0.01% | 1472 |
|
|
2025
Q1 | $103M | Buy |
2,012,777
+43,706
| +2% | +$2.25M | 0.01% | 1235 |
|
|
2024
Q4 | $109M | Sell |
1,969,071
-239,517
| -11% | -$13.3M | 0.01% | 1189 |
|
|
2024
Q3 | $72.6M | Buy |
2,208,588
+323,903
| +17% | +$10.7M | 0.01% | 1501 |
|
|
2024
Q2 | $51.2M | Sell |
1,884,685
-514,233
| -21% | -$14M | ﹤0.01% | 1735 |
|
|
2024
Q1 | $87.2M | Sell |
2,398,918
-1,516,458
| -39% | -$55.1M | 0.01% | 1294 |
|
|
2023
Q4 | $79.3M | Buy |
3,915,376
+3,841,557
| +5,204% | +$77.8M | ﹤0.01% | 1970 |
|
|
2023
Q3 | $1.31M | Buy |
73,819
+23,738
| +47% | +$422K | ﹤0.01% | 4641 |
|
|
2023
Q2 | $905K | Buy |
50,081
+17,886
| +56% | +$323K | ﹤0.01% | 4892 |
|
|
2023
Q1 | $405K | Buy |
32,195
+7,338
| +30% | +$92.2K | ﹤0.01% | 5373 |
|
|
2022
Q4 | $364K | Buy |
24,857
+587
| +2% | +$8.61K | ﹤0.01% | 5393 |
|
|
2022
Q3 | $416K | Sell |
24,270
-10,849
| -31% | -$186K | ﹤0.01% | 5350 |
|
|
2022
Q2 | $512K | Buy |
35,119
+23,908
| +213% | +$349K | ﹤0.01% | 5413 |
|
|
2022
Q1 | $188K | Sell |
11,211
-27
| -0.2% | -$453 | ﹤0.01% | 5959 |
|
|
2021
Q4 | $253K | Sell |
11,238
-17,292
| -61% | -$389K | ﹤0.01% | 5937 |
|
|
2021
Q3 | $615K | Buy |
28,530
+20,248
| +244% | +$436K | ﹤0.01% | 5359 |
|
|
2021
Q2 | $241K | Buy |
+8,282
| New | +$241K | ﹤0.01% | 5920 |
|
|
2021
Q1 | – | Sell |
-6,372
| Closed | -$263K | – | 7561 |
|
|
2020
Q4 | $263K | Buy |
+6,372
| New | +$263K | ﹤0.01% | 5445 |
|